Aptabio Therapeutics, Inc.
7 clinical trials · Sponsor
◉ Watch Aptabio Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses (NCT07330674) | Aptabio Therapeutics, Inc. | 2026-02-01 |
| A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT07123415) | Aptabio Therapeutics, Inc. | 2025-10-24 |
| Efficacy and Safety Study of Isuzinaxib in Subjects With DKD (NCT06962098) | Aptabio Therapeutics, Inc. | 2025-05-26 |
| Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI (NCT05758896) | Aptabio Therapeutics, Inc. | 2023-12-27 |
| A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19. (NCT04880109) | Aptabio Therapeutics, Inc. | 2021-10-20 |
| Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy (NCT04534439) | Aptabio Therapeutics, Inc. | 2020-08-24 |
| Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers (NCT03694041) | Aptabio Therapeutics, Inc. | 2018-05-28 |
Track Aptabio Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.